Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN study.

Gynecologic oncology·2026
Same author

Associations between molecular classification and response to intra-uterine levonorgestrel device therapy in patients with medically managed endometrial cancer and endometrial intra-epithelial neoplasia: a multi-center Endometrial Cancer Molecularly Targeted Therapy (ECMT2) Consortium study.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

Ascites protects against ferroptosis and enables the peritoneal growth of ovarian cancer.

Nature communications·2026
Same author

Estrogen hormone therapy use in ovarian cancer patients under age 60 at diagnosis.

Gynecologic oncology·2026
Same author

Temsirolimus in Patients With Solid Tumors With <i>PIK3CA</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

JCO precision oncology·2026
Same author

Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma.

Nature communications·2026

Related Experiment Video

Updated: Jun 10, 2025

Tubal Cytology of the Fallopian Tube as a Promising Tool for Ovarian Cancer Early Detection
08:09

Tubal Cytology of the Fallopian Tube as a Promising Tool for Ovarian Cancer Early Detection

Published on: July 25, 2017

12.3K

NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024.

Joyce Liu1, Andrew Berchuck2, Floor J Backes3

  • 1Dana-Farber/Brigham and Women's Cancer Center.

Journal of the National Comprehensive Cancer Network : JNCCN
|October 16, 2024
PubMed
Summary
This summary is machine-generated.

The NCCN Guidelines for ovarian cancer now incorporate PARP inhibitors, offering updated treatment strategies. These insights reflect the drug class

More Related Videos

Transplantation Into the Mouse Ovarian Fat Pad
09:25

Transplantation Into the Mouse Ovarian Fat Pad

Published on: September 7, 2016

11.3K
Ex Vivo Culture of Primary Human Fallopian Tube Epithelial Cells
11:46

Ex Vivo Culture of Primary Human Fallopian Tube Epithelial Cells

Published on: May 9, 2011

19.6K

Related Experiment Videos

Last Updated: Jun 10, 2025

Tubal Cytology of the Fallopian Tube as a Promising Tool for Ovarian Cancer Early Detection
08:09

Tubal Cytology of the Fallopian Tube as a Promising Tool for Ovarian Cancer Early Detection

Published on: July 25, 2017

12.3K
Transplantation Into the Mouse Ovarian Fat Pad
09:25

Transplantation Into the Mouse Ovarian Fat Pad

Published on: September 7, 2016

11.3K
Ex Vivo Culture of Primary Human Fallopian Tube Epithelial Cells
11:46

Ex Vivo Culture of Primary Human Fallopian Tube Epithelial Cells

Published on: May 9, 2011

19.6K

Area of Science:

  • Gynecologic Oncology
  • Clinical Practice Guidelines
  • Pharmacological Treatment

Background:

  • Ovarian, fallopian tube, and primary peritoneal cancers require comprehensive management.
  • Treatment paradigms evolve with new therapeutic options.

Purpose of the Study:

  • To update the NCCN Guidelines for ovarian, fallopian tube, and primary peritoneal cancers.
  • To detail the integration of Poly (ADP-ribose) polymerase (PARP) inhibitors into treatment recommendations.

Main Methods:

  • Review of current evidence on PARP inhibitors in ovarian cancer.
  • Expert panel discussion and consensus-building for guideline updates.

Main Results:

  • NCCN Guidelines now include PARP inhibitors for maintenance and single-agent therapy.
  • Recommendations reflect the evolving role of PARP inhibitors in ovarian cancer treatment.

Conclusions:

  • Updated NCCN Guidelines provide current recommendations for ovarian cancer management.
  • The incorporation of PARP inhibitors signifies advancements in treating these gynecologic malignancies.